AUD 0.02
(0.0%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 | 42.53 Thousand AUD | 269.22% |
2023 | 11.51 Thousand AUD | -69.76% |
2022 | 38.09 Thousand AUD | 0.56% |
2021 | 37.88 Thousand AUD | -34.83% |
2020 | 58.12 Thousand AUD | 0.0% |
2019 | - AUD | 0.0% |
2018 | - AUD | -100.0% |
2017 | 5973.00 AUD | -62.67% |
2016 | 16 Thousand AUD | 0.0% |
2015 | 16 Thousand AUD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 FY | 42.53 Thousand AUD | 269.22% |
2024 Q2 | 400.47 Thousand AUD | 3376.6% |
2024 Q4 | 42.53 Thousand AUD | -89.38% |
2023 Q2 | 25.02 Thousand AUD | 0.0% |
2023 FY | 11.51 Thousand AUD | -69.76% |
2023 Q4 | 11.51 Thousand AUD | 0.0% |
2022 FY | 38.09 Thousand AUD | 0.56% |
2022 Q2 | 50.81 Thousand AUD | 0.0% |
2022 Q4 | 38.09 Thousand AUD | 0.0% |
2021 Q2 | 24.78 Thousand AUD | 0.0% |
2021 FY | 37.88 Thousand AUD | -34.83% |
2021 Q4 | 37.88 Thousand AUD | 0.0% |
2020 Q4 | 58.12 Thousand AUD | 0.0% |
2020 FY | 58.12 Thousand AUD | 0.0% |
2020 Q2 | 50.34 Thousand AUD | 0.0% |
2019 Q4 | - AUD | 0.0% |
2019 FY | - AUD | 0.0% |
2019 Q2 | - AUD | 0.0% |
2018 Q4 | - AUD | 0.0% |
2018 FY | - AUD | -100.0% |
2018 Q2 | - AUD | 0.0% |
2017 Q1 | - AUD | 0.0% |
2017 FY | 5973.00 AUD | -62.67% |
2017 Q4 | 60.97 Thousand AUD | 0.0% |
2017 Q3 | - AUD | 0.0% |
2016 FY | 16 Thousand AUD | 0.0% |
2015 FY | 16 Thousand AUD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
EZZ Life Science Holdings Limited | 123.85 Thousand AUD | 65.662% |
Anatara Lifesciences Ltd | - AUD | -Infinity% |
Zelira Therapeutics Limited | 5.65 Million AUD | 99.248% |
Biome Australia Limited | 1.3 Million AUD | 96.743% |
Patrys Limited | - AUD | -Infinity% |
Orthocell Limited | 689.69 Thousand AUD | 93.833% |
Imugene Limited | 1.54 Million AUD | 97.251% |
Noxopharm Limited | - AUD | -Infinity% |
PYC Therapeutics Limited | 1.11 Million AUD | 96.178% |
Chimeric Therapeutics Limited | - AUD | -Infinity% |
Prescient Therapeutics Limited | 330.48 Thousand AUD | 87.131% |
Proteomics International Laboratories Limited | 316.39 Thousand AUD | 86.558% |
Cynata Therapeutics Limited | - AUD | -Infinity% |
CSL Limited | 18.24 Billion AUD | 100.0% |
Arovella Therapeutics Limited | - AUD | -Infinity% |
Bio-Gene Technology Limited | - AUD | -Infinity% |
Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | 95.166% |
Starpharma Holdings Limited | 3.52 Million AUD | 98.795% |
Memphasys Limited | 4.41 Million AUD | 99.036% |
Invex Therapeutics Ltd | - AUD | -Infinity% |
NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
Amplia Therapeutics Limited | 1.56 Million AUD | 97.277% |
Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
Island Pharmaceuticals Limited | 421.96 Thousand AUD | 89.921% |
Race Oncology Limited | - AUD | -Infinity% |
Nyrada Inc. | - AUD | -Infinity% |
Telix Pharmaceuticals Limited | 17.44 Million AUD | 99.756% |
Dimerix Limited | 149.68 Thousand AUD | 71.587% |
PharmAust Limited | - AUD | -Infinity% |
Immutep Limited | 1.22 Million AUD | 96.537% |
Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
Alterity Therapeutics Limited | 159.04 Thousand AUD | 73.259% |
BTC Health Limited | - AUD | -Infinity% |
Acrux Limited | 1.48 Million AUD | 97.14% |
Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
Biotron Limited | 7130.00 AUD | -496.494% |
Tissue Repair Ltd | - AUD | -Infinity% |
AdAlta Limited | 2.49 Million AUD | 98.295% |
Radiopharm Theranostics Limited | - AUD | -Infinity% |
Hexima Limited | - AUD | -Infinity% |
AnteoTech Limited | 23.59 Thousand AUD | -80.273% |
Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | 82.23% |
Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | 94.757% |
Avecho Biotechnology Limited | 175.15 Thousand AUD | 75.718% |
Actinogen Medical Limited | 319.06 Thousand AUD | 86.671% |
Immuron Limited | 173.49 Thousand AUD | 75.487% |
Argenica Therapeutics Limited | - AUD | -Infinity% |